Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Sandra Marten, MD, Luise Tittl, Christiane Naue, MD, Jan Beyer-Westendorf, MD

Blood (2019) 134 (Supplement_1): 3667.

https://doi.org/10.1182/blood-2019-126535

Published: 2019

Journal Articles

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Kelly L. Schoenbeck, MD, Giselle Salmasi, MD, Miguel Carlos Cerejo, DO, Patricia A. Cornett, MD, Lloyd E. Damon, MD, Aaron C. Logan, MD PhD, Rebecca L. Olin, MD, Andrew D. Leavitt, MD, Catherine C. Smith, MD

Blood (2019) 134 (Supplement_1): 1165.

https://doi.org/10.1182/blood-2019-129705

Published: 2019

Journal Articles

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

John C. Byrd, MD, Jennifer A. Woyach, MD, Richard R. Furman, MD, Peter Martin, FRCPC, MD MS, Susan M. O'Brien, MD, Jennifer R. Brown, MD PhD, Deborah M. Stephens, Jacqueline C. Barrientos, MD, Stephen Devereux, PhD, Peter Hillmen, MB ChB, PhD FRCP, FRCPath, John M. Pagel, MD PhD, Dih-Yih Chen, MD, Ahmed Hamdy, MD, Raquel Izumi, PhD, Priti Patel, MD, Min Hui Wang, PhD, Nitin Jain, MD, William G. Wierda, MD PhD

Blood (2018) 132 (Supplement 1): 692.

https://doi.org/10.1182/blood-2018-99-110451

Published: 2018

Journal Articles

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Loretta J. Nastoupil, MD, Hun Ju Lee, MD, F. B. Hagemeister, MD, Jason R. Westin, MD, Felipe Samaniego, MD, Lei Feng, MS, Jiffin John, Sheryl G Forbes, Luis E. Fayad, Michael R Green, PhD, R. Eric Davis, MD, Sattva S. Neelapu, MD, Nathan H. Fowler, MD

Blood (2018) 132 (Supplement 1): 447.

https://doi.org/10.1182/blood-2018-99-113721

Published: 2018

Journal Articles

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Spero R Cataland, MD, Marie Scully, MD MRCP, FRCPath, Flora Peyvandi, MD PhD, Paul Coppo, MD PhD, Paul Knöbl, MD PhD, Johanna A. Kremer Hovinga, MD Prof, Ara Metjian, MD, Javier De La Rubia, MD, Katerina Pavenski, MD, Jessica Minkue, Rui Passos Sousa, MD MSc, Filip Callewaert, PhD, Hilde De Winter, MD

Blood (2018) 132 (Supplement 1): 1142.

https://doi.org/10.1182/blood-2018-99-112179

Published: 2018

Journal Articles

Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study

Anca Prica, MD, Vinita Dhir, Manjula Maganti, MSc, Vishal Kukreti, MD, John Kuruvilla, MD, Michael Crump

Blood (2018) 132 (Supplement 1): 4843.

https://doi.org/10.1182/blood-2018-99-115400

Published: 2018

Journal Articles

Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study

Anastasia Tsagianni, MD, Margaret V. Ragni, MD MPH, Diane M. Comer, BS, Jonathan G. Yabes, PhD

Blood (2018) 132 (Supplement 1): 1179.

https://doi.org/10.1182/blood-2018-99-111731

Published: 2018

Journal Articles

Aspirin Thromboprophylaxis in Joint Replacement Surgery

Anish V. Sharda, MBBS, MPH, Ken A. Bauer, MD

Blood (2017) 130 (Supplement 1): 702.

https://doi.org/10.1182/blood.V130.Suppl_1.702.702

Published: 2017

Journal Articles

Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial

Gerald A. Soff, MD, Yimei Miao, BS, Sean M. Devlin, PhD, Simon Mantha, MD MPH, Jodi V Mones, MD, Valery J Li, MD, Ghassan K Abou-Alfa, MD MBA, Andrea Cercek, MD, Nancy Kemeny, MD, Rekha Parameswaran, MD

Blood (2017) 130 (Supplement 1): 289.

https://doi.org/10.1182/blood.V130.Suppl_1.289.289

Published: 2017

Journal Articles

Splanchnic Vein Thrombosis in Overt Myeloproliferative Neoplasms: The Mayo Clinic Experience with 107 Unselected Consecutive Cases

Sravanthi Lavu, MBBS, Naseema Gangat, MBBS, Animesh Pardanani, MBBS PhD, Curtis A. Hanson, MD, Rhett P. Ketterling, MD, Aneel A. Ashrani, MD, Patrick S Kamath, MD, Ayalew Tefferi, MD

Blood (2017) 130 (Supplement 1): 2925.

https://doi.org/10.1182/blood.V130.Suppl_1.2925.2925

Published: 2017

Journal Articles

Clinical Risk Factors Associated with Recurrent Venous Thromboembolism and Major Bleeding in Gastrointestinal Cancer Patients Receiving Doacs for Secondary Thromboprophylaxis

Alejandro Recio Boiles, MD, Jessica Vondrak, MD, Kristopher J. Abbate, AB, Hani M. Babiker, MD, Aaron J. Scott, MD, Ali McBride, PharmD, MS, BCPS, BCOP, Emad Elquza, MD MBA

Blood (2017) 130 (Supplement 1): 4918.

https://doi.org/10.1182/blood.V130.Suppl_1.4918.4918

Published: 2017

Journal Articles

Outpatients with Lymphoma on Chemotherapy: Specific Thromboembolic Risk Factors and Venous Thrombosis Incidence

Maria Eva Mingot-Castellano, PhD MD, Jorge Díez-Pastor, MD, Irene Sánchez-Bazán, MD, Olga Benítez, MD, Manuel Espeso de Haro, MD, Ana Isabel Heiniger, MD

Blood (2017) 130 (Supplement 1): 4908.

https://doi.org/10.1182/blood.V130.Suppl_1.4908.4908

Published: 2017

Journal Articles

Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies

Puja Arora, MD, Laura Hanson, MD, Kristine Gade, MD, Lindsey J. Hathaway, MD, Surabhi Palkimas, PharmD, Hillary S. Maitland, MDMS, Craig A. Portell, MD

Blood (2017) 130 (Supplement 1): 3723.

https://doi.org/10.1182/blood.V130.Suppl_1.3723.3723

Published: 2017

Journal Articles

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients

Robert J Charnigo, MS, Beesan Tan, PhD, Denis Rybin, PhD, Debra D Pittman, MS, Krupa M. Sivamurthy, MBBS, MD, David Beidler, PhD, Nicholas Clarke, PhD

Blood (2017) 130 (Supplement 1): 3558.

https://doi.org/10.1182/blood.V130.Suppl_1.3558.3558

Published: 2017

Journal Articles

Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy

Sven Pannach, MD, Julia Goetze, Luise Tittl, B.Sc., Thomas Schreier, Sandra Marten, MD, Jochen Hampe, MD, Jan Beyer-Westendorf, MD

Blood (2016) 128 (22): 141.

https://doi.org/10.1182/blood.V128.22.141.141

Published: 2016

Journal Articles

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, MD, Patrick J. Stiff, MD, Michele Maharaj, RN, OCN, CCRP, Katherine Oliver, BS, CCRP, Natalie Scott Callander, MD

Blood (2016) 128 (22): 4485.

https://doi.org/10.1182/blood.V128.22.4485.4485

Published: 2016

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Ravi Vij, MBBS, MD, Michael Savona, MD, David S. Siegel, MD PhD, Jonathan L. Kaufman, MD, Ashraf Badros, MD, Irene M. Ghobrial, MD, Agne Paner, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD PhD, Joseph R. Mikhael, MD, Prashant Kapoor, MD, Linda L. Neuman, MD MBA, Ju RueyJiuan Lee, PhD, Jesus G. Berdeja, MD

Blood (2014) 124 (21): 34.

https://doi.org/10.1182/blood.V124.21.34.34

Published: 2014

Journal Articles

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

Ayalew Tefferi, MD, Betsy R. LaPlant, MS, Kebede Begna, MD, Mrinal M. Patnaik, MBBS, Terra L Lasho, PhD, Darci Zblewski, CNP, Christy Finke, BS, Lauren Schimek, Adam Pettinger, Curtis A. Hanson, MD, Naseema Gangat, MD, Animesh Pardanani, MBBS, PhD

Blood (2014) 124 (21): 634.

https://doi.org/10.1182/blood.V124.21.634.634

Published: 2014

Journal Articles

FEIBA™ for Reversal of Direct Oral Anticoagulant Associated Major Bleeding

Joseph Shaw, B.Sc, Gregoire Le Gal, MDPhD, Melanie Tokessy, Nancy Cober, Elianna Saidenberg, MD, Marc Carrier, MDMSc, Lana Castellucci, MDMSc

Blood (2014) 124 (21): 1540.

https://doi.org/10.1182/blood.V124.21.1540.1540

Published: 2014

NARROW

Patterns of VTE Treatment with Noac in Cancer Patients - Results of the Prospective Dresden Noac Registry (NCT01588119)

Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms

Acalabrutinib in Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL): Updated Results from the Phase 1/2 ACE-CL-001 Study

Safety and Efficacy of Ibrutinib in Combination with Rituximab and Lenalidomide in Previously Untreated Subjects with Follicular and Marginal Zone Lymphoma: An Open Label, Phase II Study

Risk Factors and Manageability of the Mainly Mild Mucocutaneous Bleeding Profile Observed in Attp Patients Treated with Caplacizumab during the Phase III Hercules Study

Functional Predictors of Chemotherapy Toxicity in Elderly Lymphoma Patients: A Prospective Pilot Study

Von Willebrand Disease and Gastrointestinal Bleeding: A National Inpatient Sample (NIS) Study

Aspirin Thromboprophylaxis in Joint Replacement Surgery

Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT). Results of a Phase 2 Trial

Splanchnic Vein Thrombosis in Overt Myeloproliferative Neoplasms: The Mayo Clinic Experience with 107 Unselected Consecutive Cases

Clinical Risk Factors Associated with Recurrent Venous Thromboembolism and Major Bleeding in Gastrointestinal Cancer Patients Receiving Doacs for Secondary Thromboprophylaxis

Outpatients with Lymphoma on Chemotherapy: Specific Thromboembolic Risk Factors and Venous Thrombosis Incidence

Safety and Efficacy of Direct Oral Anticoagulants in Comparison to Low Molecular Weight Heparin in Hematological Malignancies

Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients

Localization, Management, Resource Consumption and Outcome of Major Gastrointestinal Bleeding in Patients with Direct Oral Anticoagulants, Vka and Antiplatelet Therapy

Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Clinical Profile of Single-Agent Oprozomib in Patients (Pts) with Multiple Myeloma (MM): Updated Results from a Multicenter, Open-Label, Dose Escalation Phase 1b/2 Study

Imetelstat, a Telomerase Inhibitor, Therapy for Myelofibrosis: A Pilot Study

FEIBA™ for Reversal of Direct Oral Anticoagulant Associated Major Bleeding

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only